We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+20.65%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$330M
AUM Growth
+$6.54M
Cap. Flow
+$45.9M
Cap. Flow %
13.92%
Top 10 Hldgs %
38.17%
Holding
104
New
22
Increased
33
Reduced
18
Closed
24

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$17.8M
2
URGN icon
UroGen Pharma
URGN
+$8.17M
3
MRSN
Mersana Therapeutics
MRSN
+$7.61M
4
GOSS icon
Gossamer Bio
GOSS
+$7.06M
5
CBAY
Cymabay Therapeutics
CBAY
+$5.7M

Top Sells

Rank Stock Value
1
SDGR icon
Schrodinger
SDGR
+$10.3M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$10.2M
3
AKRO
Akero Therapeutics
AKRO
+$9.78M
4
KRYS icon
Krystal Biotech
KRYS
+$5.78M
5
ETNB
89bio
ETNB
+$5.64M

Sector Composition

Rank Sector Weight
1 Healthcare 81.31%
2 Consumer Staples 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
51
DELISTED
Akero Therapeutics
AKRO
$1.58M 0.48%
31,336
-210,021
-87% -$9.78M
ACRS icon
52
CALL
Aclaris Therapeutics
ACRS
$743M
$1.36M 0.41%
199,000
-452,400
-69% -$3.87M
JBIO
53
Jade Biosciences
JBIO
$1.22B
$1.36M 0.41%
+2,857
New +$1.55M
PRTA icon
54
Prothena Corp
PRTA
$440M
$1.28M 0.39%
26,629
-23,092
-46% -$1.37M
ROIV icon
55
Roivant Sciences
ROIV
$24.8B
$1.17M 0.35%
+100,000
New +$1.13M
ALKS icon
56
Alkermes
ALKS
$8.39B
$1.16M 0.35%
41,455
+1,455
+4% +$42.7K
SRPT icon
57
Sarepta Therapeutics
SRPT
$1.64B
$1.11M 0.34%
9,197
-20,663
-69% -$2.34M
MRSN
58
CALL
DELISTED
Mersana Therapeutics
MRSN
$1.02M 0.31%
32,064
-11,936
-27% -$567K
ANNX icon
59
Annexon
ANNX
$863M
$943K 0.29%
399,716
+9,805
+3% +$29.7K
ETNB
60
DELISTED
89bio
ETNB
$930K 0.28%
60,247
-336,250
-85% -$5.64M
BMRN icon
61
BioMarin Pharmaceuticals
BMRN
$11.7B
$885K 0.27%
10,000
– –
SGMT icon
62
Sagimet Biosciences
SGMT
$451M
$880K 0.27%
+100,000
New +$1.33M
SDGR icon
63
Schrodinger
SDGR
$1.15B
$857K 0.26%
30,311
-255,858
-89% -$10.3M
VYGR icon
64
Voyager Therapeutics
VYGR
$189M
$806K 0.24%
103,966
+3,966
+4% +$36.2K
KPTI icon
65
Karyopharm Therapeutics
KPTI
$159M
$753K 0.23%
37,464
+2,865
+8% +$64.3K
VRDN icon
66
Viridian Therapeutics
VRDN
$2.2B
$728K 0.22%
47,438
+2,438
+5% +$46.5K
PNT
67
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$625K 0.19%
93,700
– –
RZLT icon
68
Rezolute
RZLT
$470M
$572K 0.17%
433,240
-66,304
-13% -$108K
ALGS icon
69
Aligos Therapeutics
ALGS
$26.7M
$472K 0.14%
25,275
– –
CGEN icon
70
Compugen
CGEN
$220M
$326K 0.1%
350,188
+20,000
+6% +$22K
CLYM
71
Climb Bio
CLYM
$692M
$319K 0.1%
121,110
-372,979
-75% -$1.02M
RLMD icon
72
Relmada Therapeutics
RLMD
$562M
$300K 0.09%
+100,000
New +$297K
SNDX icon
73
Syndax Pharmaceuticals
SNDX
$1.73B
$290K 0.09%
20,000
– –
ELOX
74
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$260K 0.08%
54,075
– –
BHVN icon
75
Biohaven
BHVN
$2.08B
$260K 0.08%
10,000
-10,000
-50% -$208K
1 2
3
4 5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Silverarc Capital Management held 104 positions worth $330M, up 2% from $323M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Silverarc Capital Management deployed $45.9M of net new capital in Q3 2023, opening 22 new positions and adding to 33 existing holdings. Its largest new stake was UroGen Pharma: 508,883 shares worth $7.13M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 92% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Schrodinger, an estimated $10.3M trimmed.

  • Silverarc Capital Management's largest Q3 2023 buy was UroGen Pharma: 508,883 shares worth $7.13M.
  • Silverarc Capital Management added most to Morphic Holding, Inc. Common Stock in Q3 2023, an estimated $17.8M increase.
  • Silverarc Capital Management's biggest Q3 2023 reduction was Schrodinger, cutting an estimated $10.3M.
  • Silverarc Capital Management fully exited MoonLake Immunotherapeutics in Q3 2023, selling an estimated $10.2M.
  • Silverarc Capital Management's ten largest holdings make up 38% of its $330M portfolio in Q3 2023.
  • Silverarc Capital Management opened 22 new positions and closed 24 in Q3 2023.
  • Silverarc Capital Management's portfolio value rose 2% quarter-over-quarter to $330M.

Based on Silverarc Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.